Clinical trials: Advanced Solid Cancer
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
Solid Tumor
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20~182 subjects,and a phase 2 to explore…
- Trial name
- NCT05923008
- Testing
- IBI130
- Where
- Australia
- Volunteers
- 182 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
- Trial name
- DUAL-NK-BC (NCT07486089)
- Testing
- Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Neoplasms, Lymphoma
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
This is an open label, dose escalation, phase I study of the combination of MLN9708 plus Nelfinavir.
- Trial name
- NCT03422874
- Testing
- MLN9708, Nelfinavir
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
SJG-136 in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as SJG-136, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00103220
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness…
- Trial name
- NCT00024310
- Testing
- folic acid, lometrexol, paclitaxel
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumour
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid…
- Trial name
- NCT01300468
- Testing
- PHA-848125AC
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Nerviano Medical Sciences
Neoplasms
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation.
- Trial name
- NCT03564691
- Testing
- MK-4830, Pembrolizumab, Carboplatin
- Where
- 37 sites in United States, Australia and 10 more
- Volunteers
- 470 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Solid Tumor, Metastatic Cancer
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan.
- Conditions
- Malignant Solid Tumor, Metastatic Cancer, Advanced Cancer
- Trial name
- PAYLOAD (NCT02801097)
- Testing
- RRx-001, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- EpicentRx, Inc.
Colorectum Advanced Malignancies, Breast Advanced Malignancies
Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies
The purpose of this study is to assess whether the presence of a Myelodysplastic Syndrome (MDS) , Idiopathic Cytopenia of Undetermined Significance (ICUS) or Idiopathic Dysplasia of Undetermined Significance (IDUS), correlates…
- Conditions
- Colorectum Advanced Malignancies, Breast Advanced Malignancies, Prostate Advanced Malignancies
- Trial name
- OptiMal (NCT01956747)
- Testing
- venapunction, bone marrow punction
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Advanced Solid Tumor, Non Small Cell Lung Cancer
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT04440735
- Testing
- DSP107, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- Kahr Medical
Advanced Cancers
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer.
- Trial name
- NCT01200004
- Testing
- Azacitidine, Lenalidomide, Grifola Frondosa
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Classic Hodgkin Lymphoma
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPα Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas.
- Trial name
- NCT05833984
- Testing
- IMM01, Tislelizumab
- Where
- 5 sites in China
- Volunteers
- 309 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Solid Tumors
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.
- Trial name
- NCT01127178
- Testing
- E7016 + TMZ
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eisai Inc.
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic…
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma
- Trial name
- SURF301 (NCT05544552)
- Testing
- TYRA-300
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 310 people
- Sponsor
- Tyra Biosciences, Inc
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Solid Tumor
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
Open-label, multicenter, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study.
- Trial name
- PEG (NCT00834704)
- Testing
- PEGPH20
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Solid Tumors
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
AC480IV will be administered as a monotherapy and then in combination with docetaxel in patients with locally advanced or metastatic solid tumors for whom there are no standard or curative therapies available.
- Trial name
- NCT01245543
- Testing
- AC480IV, Docetaxel
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.